Skip to main content
SpringerLink
Log in

Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case–control study

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Previous studies suggest that antiepileptic drugs with histone deacetylase (HDAC) inhibitor properties may have prostate cancer preventive effects. We evaluated the association between antiepileptic drug use and prostate cancer risk in a population-based case–control study. The study included all new prostate cancer cases diagnosed in Finland in 1995–2002 and matched controls (24,657 case–control pairs) identified from the Finnish Cancer Registry and the Population Register Center, respectively. Information on antiepileptic drug purchases was obtained from the national prescription reimbursement database. Odds ratios and their 95 % confidence intervals were estimated using age-adjusted and multivariable-adjusted conditional logistic regression analysis. Compared to never-users of antiepileptic drugs, the overall prostate cancer risk was decreased among users of phenobarbital, carbamazepine, and valproic acid (multivariable-adjusted odds ratio (OR) 0.47, 95 % CI 0.24–0.92; OR 0.82, 95 % CI 0.71–0.94, and OR 0.62, 95 % CI 0.42–0.92, respectively), but not among users of other antiepileptic drugs. Overall prostate cancer risk decreased in a dose-dependent manner by cumulative amount, duration and yearly dosage (intensity) of HDAC inhibitors valproic acid and carbamazepine. The risk of advanced prostate cancer was decreased only among carbamazepine users (OR 0.65, 95 % CI 0.44–0.96). Our results support possible prostate cancer preventive effects of HDAC inhibitors. However, also phenobarbital use was associated with decreased prostate cancer risk, despite not having HDAC inhibiting activity. The mechanism of action for antiepileptic drugs in prostate cancer deserves further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907

    Article  Google Scholar 

  2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  3. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737–744

    Article  CAS  PubMed  Google Scholar 

  4. Batta K, Das C, Gadad S, Shandilya J, Kundu TK (2007) Reversible acetylation of non histone proteins: role in cellular function and disease. Subcell Biochem 41:193–212

    Article  PubMed  Google Scholar 

  5. Iacopino F, Urbano R, Graziani G, Muzi A, Navarra R, Sica G (2008) Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int J Oncol 32:1293–1303

    CAS  PubMed  Google Scholar 

  6. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237–7244

    Article  CAS  PubMed  Google Scholar 

  7. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA (2007) Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67:1099–1110

    Article  CAS  PubMed  Google Scholar 

  8. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen J, Kaulfuss S (2012) Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis 34:1115–1124

    Article  Google Scholar 

  9. Stettner M, Kramer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, Thelen P (2012) Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev 21:55–64

    Article  CAS  PubMed  Google Scholar 

  10. Singh G, Bell GS, Driever PH, Sander JW (2012) Cancer risk in people with epilepsy using valproate-sodium. Acta Neurol Scand 125:234–240

    Article  CAS  PubMed  Google Scholar 

  11. Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR, Brandes JC (2014) Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer 120:1394–1400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hallas J, Friis S, Bjerrum L, Stovring H, Narverud SF, Heyerdahl T, Gronbaek K, Andersen M (2009) Cancer risk in long-term users of valproate: a population-based case–control study. Cancer Epidemiol Biomark Prev 18:1714–1719

    Article  Google Scholar 

  13. Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Acta Oncol 33:365–369

    Article  CAS  PubMed  Google Scholar 

  14. Martikainen J, Rajaniemi S (2002) Drug reimbursement systems in EU member states, Iceland and Norway. The Social Insurance Institution, Finland, Social security and health reports 54, 2002, Helsinki, Finland. http://www.kela.fi/web/en/reimbursements-for-medicine-expences

  15. Rosenbaum PR, Rubin DB (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516–524

    Article  Google Scholar 

  16. Beutler AS, Li S, Nicol R, Walsh MJ (2005) Carbamazepine is an inhibitor of histone deacetylases. Life Sci 76:3107–3115

    Article  CAS  PubMed  Google Scholar 

  17. Heaney DC, MacDonald BK, Everitt A, Stevenson S, Leonardi GS, Wilkinson P, Sander JW (2002) Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. BMJ 325:1013–1016

    Article  PubMed  PubMed Central  Google Scholar 

  18. Steer S, Pickrell WO, Kerr MP, Thomas RH (2014) Epilepsy prevalence and socioeconomic deprivation in England. Epilepsia 55:1634–1641

    Article  PubMed  Google Scholar 

  19. Pukkala E, Weiderpass E (2002) Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971–95. Int J Cancer 102:643–648

    Article  CAS  PubMed  Google Scholar 

  20. Månsson R, Joffe MM, Sun W, Hennessy S (2007) On the estimation and use of propensity scores in case–control and case-cohort studies. Am J Epidemiol 166:332–339

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study received research grants from Finnish cultural foundation and Pirkanmaa Hospital District.

Author information

Authors and Affiliations

  1. School of Medicine, University of Tampere, Medisiinarinkatu 3, 33014, Tampere, Finland

    Jukka K. Salminen, Teuvo L. J. Tammela & Teemu J. Murtola

  2. Department of Urology, Tampere University Hospital, Tampere, Finland

    Teuvo L. J. Tammela & Teemu J. Murtola

  3. School of Health Sciences, University of Tampere, Tampere, Finland

    Anssi Auvinen

Authors
  1. Jukka K. Salminen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teuvo L. J. Tammela
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anssi Auvinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teemu J. Murtola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jukka K. Salminen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salminen, J.K., Tammela, T.L.J., Auvinen, A. et al. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case–control study. Cancer Causes Control 27, 637–645 (2016). https://doi.org/10.1007/s10552-016-0737-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-016-0737-2

Keywords

Search

Navigation